Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie-Reference-Cited by-同舟云学术

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Published:2015-03 Issue:5 Volume:51 Page:569-576
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lorenzen Sylvie,Riera Knorrenschild Jorge,Haag Georg-Martin,Pohl Michael,Thuss-Patience Peter,Bassermann Florian,Helbig Ulrike,Weißinger Florian,Schnoy Elisabeth,Becker Klaus,Stocker Gertraud,Rüschoff Josef,Eisenmenger Andreas,Karapanagiotou-Schenkel Irini,Lordick Florian

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

2. The use of confidence or fiducial limits illustrated in the case of the binomial;Clopper;Biometrika,1934

3. Modelling survival data in medical research;Colette,1994

4. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial;Ford;Lancet Oncol,2014

5. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments;Cancers;2024-03-29

2. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer;Gastric Cancer;2023-10-17

3. Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA;Drugs - Real World Outcomes;2023-08-04

4. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?;Bulletin du Cancer;2023-05

5. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer;International Journal of Molecular Sciences;2022-09-08